Results 21 to 30 of about 354,007 (274)

The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial [PDF]

BMC Cancer, 2020
Background Leukotriene receptor antagonists (LTRAs) are broadly used for the management of allergic asthma and have recently been indicated to inhibit carcinogenesis and cancer cell growth.
Takuma Higurashi, Jun Arimoto, Keiichi Ashikari, Tomohiro Takatsu, Noboru Misawa, Tsutomu Yoshihara, Tetsuya Matsuura, Akiko Fuyuki, Hidenori Ohkubo, Atsushi Nakajima   +9 more
doaj   +2 more sources

Cysteine Leukotriene Receptor Antagonist—Montelukast—Treatment Improves Experimental Abdominal Aortic Aneurysms in Mice [PDF]

Cardiovascular Therapeutics
Conclusion: Montelukast treatment improves experimental nondissected AAAs in mice partly by improving aortic inflammation.
Kexin Li, Meng Li, Panpan Wei, Kangli Tian, Haole Liu, Weilai Fu, Haiwen Hou, Yajie Chen, Baohui Xu, Yankui Li, Sihai Zhao   +10 more
doaj   +2 more sources

Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease

Journal of Allergy and Clinical Immunology, 2012
Li Yin, Magnus Bäck, Erik Ingelsson
exaly   +2 more sources

Role of Antileukotrienes In Prevention of Recurrence of Nasal Polyps [PDF]

Zagazig University Medical Journal, 2023
Background: Nasal polyps are common in patients with chro nic rhinosinusitis, yet, to date, little is known about the pathophysiology of nasal polyp formation. This study aimed to determine the effect of montelukast (a leukotriene receptor antagonist) as
Samir Sorour, Yehia AbouShab, Abdul Zaher Tantawy, Ahmed Abdel Rahman   +3 more
doaj   +1 more source

Leukotriene Receptor Antagonists [PDF]

Seminars in Respiratory and Critical Care Medicine, 2002
In the past decade, heightened emphasis has been placed on the importance of inflammation in the pathogenesis of asthma. Although corticosteroids have remained the primary anti-inflammatory agents in the management of the persistent asthmatic, new classes of drugs have recently been added.
Marzena E, Krawiec, Nizar J, Jarjour
openaire   +2 more sources

Leukotrienes, leukotriene receptor antagonists, and rhinitis [PDF]

Allergy, 2000
A series of clinical studies have shown the ef®cacy of leukotriene (LT) receptor antagonists (LTRAs) in the treatment of bronchial asthma (1±6). LTRAs relieve bronchospasm, prevent exercise-induced asthma, and reduce bronchial hyperresponsiveness.
N, Mygind, R, Dahl, H, Bisgaard
openaire   +2 more sources

Leukotriene receptor antagonists for eczema [PDF]

Cochrane Database of Systematic Reviews, 2018
Eczema is a common, chronic, inflammatory skin condition that is frequently associated with atopic conditions, including asthma. Leukotriene receptor antagonists (LTRAs) have a corticosteroid-sparing role in asthma, but their role in eczema remains controversial.
Leila, Ferguson, Masaki, Futamura, Efstratios, Vakirlis, Reiji, Kojima, Hatoko, Sasaki, Amanda, Roberts, Rintaro, Mori   +6 more
openaire   +2 more sources

Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction‐associated fatty liver disease

Hepatology, EarlyView., 2022
Increased liver content of DHA‐derived small lipid autacoids (i.e resolvin D1 and maresin 1) associates with enhanced mitochondrial oxidative phosphorylation, fatty acid β‐oxidation and bioenergetic metabolic flux. These features provide hepatic protection from steatotic, pro‐inflammatory and fibrogenic insults.
Cristina López‐Vicario, David Sebastián, Mireia Casulleras, Marta Duran‐Güell, Roger Flores‐Costa, Ferran Aguilar, Juan José Lozano, Ingrid W. Zhang, Esther Titos, Jing X. Kang, Antonio Zorzano, Makoto Arita, Joan Clària   +12 more
wiley   +1 more source

Comparative Study to Assess Clinical Efficacy of Leukotriene Receptor Antagonist and Antihistamines in the Treatment of Allergic Rhinitis

Bengal Journal of Otolaryngology and Head Neck Surgery, 2017
Introduction Pharmacologic treatment  options for allergic rhinitis include intranasal corticosteroids, oral and topical antihistamines, decongestants, intranasal cromolyn, intranasal anticholinergics and leukotriene receptor antagonists.
Gurpreet Kaur, Rachna Dhingra, Manjinder Singh   +2 more
doaj   +3 more sources

Cysteinyl leukotriene receptor 1 is dispensable for osteoclast differentiation and bone resorption.

PLoS ONE, 2022
Cysteinyl leukotriene receptor 1 (CysLTR1) is a G protein-coupled receptor for the inflammatory lipid mediators cysteinyl leukotrienes, which are involved in smooth muscle constriction, vascular permeability, and macrophage chemokine release. The Cysltr1
Hirofumi Fujita, Aoi Ando, Yohei Mizusawa, Mitsuaki Ono, Takako Hattori, Munenori Habuta, Toshitaka Oohashi, Satoshi Kubota, Hideyo Ohuchi   +8 more
doaj   +1 more source